Will You Be in San Diego February 6th and 7th? Be Our Guest at the 2nd Annual Biomarker Conference
Due to the overwhelming response to the first ever Biomarker Conference last year, scheduled attendance for the 2nd Annual Biomarker Conference is shaping up to surpass last year’s success.
As you might suspect, the agenda is shaped around the “hot” topics in Precision Medicine: companion diagnostics (CDx), immuno-oncology (IO), and next generation sequencing (NGS).
As a leading precision oncology diagnostics company, supporting over 130 clinical studies involving biomarkers and serving 8 of the top 10 biopharma companies in the world, Cancer Genetics, Inc. (CGI) is proud to be the Platinum Sponsor of the meeting and pleased to share insights by its experts on the speaker panel.
Would you like to join us? Consider this an invitation to you and your colleagues for the meeting next Monday and Tuesday at the San Diego Marriott La Jolla. Please drop me an email to learn how to secure your complimentary spot.
Also be sure to stop by the CGI Booth!
Below is an overview of the scheduled speakers from CGI.
Drawing on CGI’s vast expertise in oncology biomarkers and molecular testing, CGI Medical Director TuDung Nguyen, MD, PhD, will cover topics related to the “Implementation of Precision Medicine in the Clinical Laboratory in the Current Era” for both solid tumors and hematological Here are the highlights of Dr. Nguyen’s talk:
- Biomarker evaluation in Solid and hematologic cancers: value of a focused vs. broad approach; role in multi-modality testing, including NGS gene panels
- Biomarker test development in clinical trials translated into clinical practice
- Insights into immunotherapy biomarker testing, especially PD-L1 IHC
|TuDung Nguyen, MD, PhD, Medical Director, CGI|
Dr. Nguyen speaks on Monday, February 6th, 11:45am.
CGI VP of Biopharma Market Development, Collaborations and Companion Diagnostics Kamala Maddali, DVM, PhD, will be on the panel titled “Complementary diagnostics vs. Companion Diagnostics – How do we ensure success in biomarker efforts?” along with other prominent panelists and will share her ideas on various aspects to be considered in biomarker development, regulatory hurdles, and how to ensure success in biomarker efforts.
|Kamala Maddali, DVM, PhD, VP, Biopharm Market Develoment, Collaborations & Companion Diagnostics, CGI|
Please attend the panel discussion with Dr. Maddali as a panelist on Monday, February 6th, 2:05pm.
CGI has been one of the important players in the revolutionary era of precision therapy with its bench to bedside approach and competitive test portfolio, which now includes extensive IO capabilities based across a variety of technologies. We’ve addressed a tremendous market demand by providing both genomic and immune-marker information to clinical trials, patient care, and translational research.CGI’s VP of Biopharma Solutions, Rob Fannonwill provide an overview of the company’s broad expertise and capabilities in IO covering the “Challenging Factors in Immuno-Oncology Clinical Trial Studies”.
- Examine the complexity of IO studies across noveldrug targets
- Explore scientific strategy, validation, and trial management of PD-L1 focused studies across multiple indications
- Case study on successful partnership between lab CRO and IO pharma partner
|Rob Fannon, MPH, MBA, VP, Biopharma Solutions|
Rob’s talk is scheduled for Tuesday, February 7th, 12:15pm.
Again, please reach out to me to receive an invitation to attend the conference free of charge and meet with any of our experts. Also stop by the CGI Booth!
Anna Israyelyan, MD, PhD
Clinical Affairs Manager
Tel: 323.224.3900 x175